We are live on ! Find out more
EC

Elmind Capital Portfolio holdings

AUM $398M
This Fund
S&P 500
This Quarter Est. Return
+12.77%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$13.4M
Cap. Flow
-$7.13M
Cap. Flow %
-2.03%
Top 10 Hldgs %
68.76%
Holding
36
New
2
Increased
7
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
CTMX icon
CytomX Therapeutics
CTMX
+$19.5M
2
DBVT
DBV Technologies
DBVT
+$5.54M
3
KALV
KalVista Pharmaceuticals
KALV
+$3.55M
4
ALMS
Alumis Inc
ALMS
+$3.25M
5
CGEM icon
Cullinan Oncology
CGEM
+$2.83M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$11.4M
2
DVAX
Dynavax Technologies
DVAX
+$10.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$9.61M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.93M
5
WVE icon
Wave Life Sciences
WVE
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
1
Cogent Biosciences
COGT
$6.58B
$45.1M 12.79%
1,170,740
– –
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.77B
$43.3M 12.3%
1,855,000
– –
CLDX icon
3
Celldex Therapeutics
CLDX
$3.29B
$27.4M 7.79%
865,000
– –
CTMX icon
4
CytomX Therapeutics
CTMX
$732M
$21.4M 6.07%
4,550,000
+3,850,000
+550% +$19.5M
KALV
5
DELISTED
KalVista Pharmaceuticals
KALV
$20.6M 5.84%
1,021,300
+220,000
+27% +$3.55M
CGON icon
6
CG Oncology
CGON
$6.65B
$19.7M 5.61%
291,800
-200,700
-41% -$11.4M
VERA icon
7
Vera Therapeutics
VERA
$2.28B
$19.4M 5.51%
482,500
– –
PCVX icon
8
Vaxcyte
PCVX
$8.64B
$18.4M 5.22%
316,500
+25,000
+9% +$1.36M
PHVS icon
9
Pharvaris
PHVS
$2.46B
$13.4M 3.82%
475,750
– –
TYRA icon
10
Tyra Biosciences
TYRA
$1.51B
$13.4M 3.81%
350,000
– –
BEAM icon
11
Beam Therapeutics
BEAM
$2.76B
$11.4M 3.22%
476,338
– –
VRDN icon
12
Viridian Therapeutics
VRDN
$2.5B
$10.5M 2.97%
534,931
-323,700
-38% -$9.61M
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.49B
$9.52M 2.7%
1,000,000
-1,150,000
-53% -$8.93M
UTHR icon
14
United Therapeutics
UTHR
$21.4B
$8.89M 2.53%
15,000
+4,000
+36% +$1.99M
CGEM icon
15
Cullinan Oncology
CGEM
$1.31B
$7.53M 2.14%
530,000
+220,000
+71% +$2.83M
NRIX icon
16
Nurix Therapeutics
NRIX
$2.81B
$7.13M 2.02%
460,000
– –
MBX
17
MBX Biosciences
MBX
$3.3B
$6.3M 1.79%
211,000
– –
KRYS icon
18
Krystal Biotech
KRYS
$9.83B
$5.68M 1.61%
22,000
– –
DBVT
19
DBV Technologies
DBVT
$881M
$5.54M 1.57%
+265,000
New +$5.54M
RLAY icon
20
Relay Therapeutics
RLAY
$4.35B
$5.34M 1.52%
536,946
– –
TVTX icon
21
Travere Therapeutics
TVTX
$5.86B
$5.28M 1.5%
177,600
+67,600
+61% +$2.02M
PTGX icon
22
Protagonist Therapeutics
PTGX
$10B
$4.01M 1.14%
38,000
– –
URGN icon
23
UroGen Pharma
URGN
$2.36B
$3.96M 1.12%
220,000
+120,000
+120% +$2.41M
ALMS
24
Alumis Inc
ALMS
$3.28B
$2.86M 0.81%
+130,000
New +$3.25M
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$13B
$2.66M 0.75%
47,000
-35,000
-43% -$2.04M
1
2

Similar funds

FFS
Fischer Financial Services Harrisburg, Pennsylvania $398M AUM 22.91% 1-Year Est. Return
SFS
Stiles Financial Services Edina, Minnesota $398M AUM 55.89% 1-Year Est. Return
SIC
Shoker Investment Counsel Oxford, Ohio $398M AUM 39.01% 1-Year Est. Return
SIAS
Summit Investment Advisory Services Roseville, Minnesota $398M AUM 21.26% 1-Year Est. Return
HVP
Hudson Value Partners Palm Beach, Florida $399M AUM 48.26% 1-Year Est. Return
AC
Alfreton Capital Radlett, Hertfordshire, United Kingdom $399M AUM 20.53% 1-Year Est. Return
W
WorthPointe La Jolla, California $399M AUM 22.49% 1-Year Est. Return
CL
COWA LLC Tulsa, Oklahoma $399M AUM 25.74% 1-Year Est. Return

Elmind Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Elmind Capital held 36 positions worth $352M, up 3.9% from $339M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Elmind Capital's Q1 2026 filing shows 2 new, 7 increased, 6 reduced and 2 closed positions. Its largest new stake was DBV Technologies: 265,000 shares worth $5.54M. The largest sale was CG Oncology, an estimated $11.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Elmind Capital's largest Q1 2026 buy was DBV Technologies: 265,000 shares worth $5.54M.
  • Elmind Capital added most to CytomX Therapeutics in Q1 2026, an estimated $19.5M increase.
  • Elmind Capital's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $11.4M.
  • Elmind Capital fully exited Dynavax Technologies in Q1 2026, selling an estimated $10.5M.
  • Elmind Capital's ten largest holdings make up 69% of its $352M portfolio in Q1 2026.
  • Elmind Capital opened 2 new positions and closed 2 in Q1 2026.
  • Elmind Capital's portfolio value rose 3.9% quarter-over-quarter to $352M.

Based on Elmind Capital's 13F filing for Q1 2026, filed 15 May 2026.